AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32101140
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment strategy including wound care (98.9%), antibiotherapy (77.5%), discontinuation of Vitamin K antagonists (VKA) (70.8%), intravenous sodium thiosulfate (65.2%)
Trial: 32101614
Drug: Triple Therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple Therapy (TT group)
Trial: 32102167
Drug: 2.67 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.67 g/day agmatine sulfate (AgmaSet)
Trial: 32102676
Drug: Propofol anesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol anesthesia (target-controlled infusion using the Schneider model)
Trial: 32102950
Drug: Pembrolizumab-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab-based therapy (alone or in combination with chemotherapy)
Trial: 32103260
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg once daily with food
Trial: 32104059
Drug: N-methyl-D-aspartate antagonists
RxNorm normalized name: N-methyl-D-glucamine
DrugBank: Meglumine (DB09415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-methyl-D-aspartate antagonists (intravenous ketamine and oral memantine)
Trial: 32104962
Drug: Simultaneous acoustic
RxNorm normalized name: aconite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous acoustic vibrations and positive expiratory pressure applied to the nasal cavity twice daily over 5 weeks
Trial: 32105293
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (HPV-6, -11, -16, and -18) administered via intramuscular injections on days 1 and 2 and then 6 months later.
Trial: 32105293
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (HPV-6, -11, -16, and -18) administered via intramuscular injections.
Trial: 32106302
Drug: Anti-interleukin-6-directed therapies
RxNorm normalized name: interleukin-6
DrugBank: Human interleukin-6 (DB15060)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-interleukin-6-directed therapies in iMCD
Trial: 32107674
Drug: General Organizational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General Organizational Index (GOI) scale administered four times over 18 months
Trial: 32109839
Drug: Mango polyphenols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mango polyphenols (200-400 g of mango pulp daily for 8 weeks)
Trial: 32110025
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate (250-1500 mg/day)
Trial: 32110060
Drug: Benralizumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab (30 mg) administered subcutaneously at Days 0, 28, and 56
Trial: 32110958
Drug: Study treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study treatment plans (de-intensified radiotherapy)
Trial: 32110958
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plans (conventional radiotherapy)
Trial: 32111348
Drug: Oral problems
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral problems associated with a low OHRQoL (GOHAI<50)
Trial: 32112982
Drug: Crizotinib (first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crizotinib (first-line therapy)
Trial: 32113581
Drug: Terlipressin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin (2 mg/day for 4 days)
Trial: 32113892
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral agents (DAAs)
Trial: 32114500
Drug: TriMixDC-MEL IPI
RxNorm normalized name: Mel
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TriMixDC-MEL IPI or subsequent pembrolizumab treatment
Trial: 32115672
Drug: VPA +
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA + dextromethorphan (30 mg/day) + memantine (5 mg/day) (DM30 + MM5)
Trial: 32115672
Drug: VPA +
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA + dextromethorphan (30 mg/day) (DM30)
Trial: 32115672
Drug: VPA +
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA + memantine (5 mg/day) (MM5)
Trial: 32116725
Drug: Angusta 25
RxNorm normalized name: LAMINARIA ANGUSTATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angusta 25 µg
Trial: 32116725
Drug: Cytotec 200
RxNorm normalized name: Cytotec 200mcg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotec 200 µg
Trial: 32116856
Drug: Family-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based treatment (FBT) with three additional sessions of Intensive Parental Coaching (IPC) after session 4.
Trial: 32116856
Drug: Standard Family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Family-based treatment (FBT) without additional IPC.
Trial: 32118022
Drug: Plasmalogens treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmalogens treatment, specific dosage and duration not available
Trial: 32118616
Drug: Enriched, task-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enriched, task-specific therapy
Trial: 32120379
Drug: QT-prolonging medications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QT-prolonging medications
Trial: 32122899
Drug: Cefpirome 2
RxNorm normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome 2 g every 8 h for intravenous bolus injection or 2 g every 12 h for extended infusion over 4 h
Trial: 32122924
Drug: Tazemetostat (EPZ-6438)
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tazemetostat (EPZ-6438) 800 mg twice a day plus R-CHOP
Trial: 32123139
Drug: Other indoor
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other indoor settings (e.g., bar and restaurant)
Trial: 32123534
Drug: MVM supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVM supplementation (single dose on Day 1 and 4-week supplementation on Day 28)
Trial: 32123534
Drug: MVM supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVM supplementation (single dose on Day 1)
Trial: 32125255
Drug: MRI with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRI with specific absorption rate (SAR) measurements
Trial: 32125937
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg per day for 6 months
Trial: 32127922
Drug: Early systematic
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early systematic supplemental parenteral nutrition (SPN) in combination with nutritional counseling (NC)
Trial: 32129861
Drug: 40 mg/kg/day,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg/day, q8h, IV drip 3 h
Trial: 32129861
Drug: 80 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/kg/day (continuous infusion)
Trial: 32129861
Drug: 160 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg/kg/day (continuous infusion)
Trial: 32129861
Drug: 20-160 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-160 mg/kg/day
Trial: 32130192
Drug: Outsmart HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outsmart HPV content on the Web with monthly unidirectional vaccination reminders sent via text messages
Trial: 32130192
Drug: Outsmart HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outsmart HPV content on the Web with monthly interactive vaccination reminders sent via text messages
Trial: 32130192
Drug: Standard information
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard information on the Web about HPV vaccine
Trial: 32130813
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bedaquiline, pretomanid, and linezolid
Trial: 32131742
Drug: Renally inappropriate
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renally inappropriate medications (RIMs)
Trial: 32131742
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors and allopurinol
Trial: 32131742
Drug: Specific medications
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific medications identified for deprescription
Trial: 32133329
Drug: Sedative treatment
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative treatment
Trial: 32134216
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of positive PCT, CRP, and DLS values
Trial: 32134216
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of negative PCT, CRP, and DLS values
Trial: 32138941
Drug: Exposure-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure-based cognitive-behavioral therapy (CBT)
Trial: 32139220
Drug: Optimized thienopyridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized thienopyridine treatment for patients with loss-of-function (LOF) alleles (class 2, n = 272)
Trial: 32140912
Drug: Inhaled or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled or nasal corticosteroids
Trial: 32140912
Drug: CYP3A4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CYP3A4 inhibitors
Trial: 32140912
Drug: CYP3A4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CYP3A4 inhibitors (specific corticosteroid: beclomethasone)
Trial: 32143664
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula therapy at 20, 40, and 60 L/min
Trial: 32143664
Drug: Baseline (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline (conventional oxygen therapy)
Trial: 32144134
Drug: Utomilumab (0.03-10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Utomilumab (0.03-10.0 mg/kg every 4 weeks) plus Rituximab (375 mg/m2)
Trial: 32145771
Drug: Enasidenib (60-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enasidenib (60-300 mg per day, oral, in repeated 28-day treatment cycles)
Trial: 32146304
Drug: Axitinib 5
RxNorm normalized name: axitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib 5 mg orally twice daily
Trial: 32146703
Drug: Zotarolimus-eluting stent
RxNorm normalized name: castor fiber scent gland secretion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zotarolimus-eluting stent (ZES) treatment
Trial: 32147213
Drug: Intratumoral delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoral delivery of plasmid encoding IL-12 (tavokinogene telseplasmid; tavo), 0.5 mg/ml followed by electroporation (six pulses, 1500 V/cm) on days 1, 5, and 8 every 90 days
Trial: 32147669
Drug: Dacomitinib (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacomitinib (15 mg) plus PD-0325901 (6 mg)
Trial: 32147671
Drug: Buparlisib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib (80 mg) in combination with imatinib (400 mg)
Trial: 32147671
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard therapies)
Trial: 32149760
Drug: Before nicorandil
RxNorm normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before nicorandil medication
Trial: 32151247
Drug: Oral antihyperglycemic
RxNorm normalized name: ANTIHYPOGLYCEMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antihyperglycemic agents with a blood glucose cut-off value of 3.9 mmol/L (70 mg/dL)
Trial: 32151247
Drug: Oral antihyperglycemic
RxNorm normalized name: ANTIHYPOGLYCEMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antihyperglycemic agents with a blood glucose cut-off value of 3.0 mmol/L (54 mg/dL)
Trial: 32152160
Drug: Early biomarkers
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early biomarkers (albuminuria, N-acetyl-beta-D-glucosaminidase, kidney injury molecule-1, neutrophil gelatinase-associated lipocalin)
Trial: 32152173
Drug: Single-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose intravenous 12/12 human leucocyte antigen-matched sibling cord blood cell infusion
Trial: 32153439
Drug: Intense manualized
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense manualized treatment for 1 month as part of the ROCKETLAUNCH project
Trial: 32153439
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment in Sweden (data from the 10 previous patients at each outpatient clinic)
Trial: 32153804
Drug: Regional and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional and socioeconomic factors, lactation stage, and supplement intake
Trial: 32153817
Drug: DDU-supplement (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDU-supplement (500 mg DHA, 10 μg vitamin D)
Trial: 32153840
Drug: Patients provided
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients provided medication for nausea as a barrier removal strategy
Trial: 32153871
Drug: Cod intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod intake twice weekly for 16 weeks (pregnancy week 20-36)
Trial: 32153879
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (3.5 kg corn/soy blended flour with 350 mL vegetable oil every two weeks)
Trial: 38966095
Drug: Routine amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine amoxicillin
Trial: 32153900
Drug: Daily preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily preventive zinc dispersible tablet
Trial: 32153900
Drug: Daily preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily preventive multiple micronutrient powder
Trial: 32153900
Drug: Therapeutic zinc
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic zinc dispersible tablet for diarrhea
Trial: 32153947
Drug: 40 g lipid-based
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g lipid-based nutrient supplement (Epi-E)
Trial: 32153959
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (30,000 IU weekly for 6 months)
Trial: 32154497
Drug: ULT (Iron-Enriched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ULT (Iron-Enriched Supplement)
Trial: 32156630
Drug: IXIARO® Japanese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IXIARO® Japanese encephalitis vaccine (2-dose primary series)
Trial: 32156743
Drug: Tirabrutinib monotherapy
RxNorm normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirabrutinib monotherapy (80 mg every day)
Trial: 32156743
Drug: Tirabrutinib in
RxNorm normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirabrutinib in combination with Idelalisib (50 mg twice a day or 100 mg every day)
Trial: 32156743
Drug: Tirabrutinib in
RxNorm normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirabrutinib in combination with Entospletinib (200 mg or 400 mg every day)
Trial: 32157590
Drug: Telotristat ethyl
RxNorm normalized name: Telotristat ethyl
DrugBank: Telotristat ethyl (DB12095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telotristat ethyl treatment
Trial: 32158272
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin and statins offered to men with AAA after the millennium (VIVA and DANCAVAS trials)
Trial: 32160294
Drug: Ruxolitinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (5 mg twice daily plus corticosteroids)
Trial: 32161584
Drug: Adjuvant ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjuvant ipilimumab co-administration with a peptide vaccine
Trial: 32161660
Drug: KAPA intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KAPA intervention (six group sessions of motivational interviewing, monthly)
Trial: 32161846
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) infusions, initially every 4 weeks, then extended to every 6 weeks for the first 3 months, with subsequent intervals determined by the clinician
Trial: 32163431
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy Text Messaging Intervention
Trial: 32164435
Drug: Isoproterenol infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoproterenol infusion during exercise testing
Trial: 32164981
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with cytotoxic chemotherapy (4 cycles)
Trial: 32165096
Drug: FOLFOX-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX-based therapy
Trial: 32167861
Drug: Bemarituzumab (FPA144)
RxNorm normalized name: Bemarituzumab
DrugBank: Bemarituzumab (DB16105)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemarituzumab (FPA144) at doses of 0.3 to 15 mg/kg every 2 weeks
Trial: 32167861
Drug: Bemarituzumab (FPA144)
RxNorm normalized name: Bemarituzumab
DrugBank: Bemarituzumab (DB16105)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemarituzumab (FPA144) at doses of ≥ 10 mg/kg every 2 weeks for ≥ 70 days
Trial: 32168224
Drug: HCV antibody
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV antibody positive women (case group)
Trial: 32168224
Drug: HCV antibody
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV antibody negative women (control group)
Trial: 32168240
Drug: Silicone-hydrogel daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone-hydrogel daily disposable contact lenses (delefilcon A)
Trial: 32168240
Drug: Hydrogel daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel daily disposable contact lenses (omafilcon A)
Trial: 32169783
Drug: Durvalumab (Du)
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab (Du) 1500 mg every 3 weeks (q3w)
Trial: 32169783
Drug: Tremelimumab (Tr)
RxNorm normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (Tr) 75 mg q3w for 5 doses
Trial: 32169783
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Du and Tr with platinum-doublet chemotherapy
Trial: 32169783
Drug: Chemotherapy (pemetrexed,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed, gemcitabine, etoposide, nab-paclitaxel with cisplatin or carboplatin)
Trial: 32169872
Drug: hu14.18K322A mAb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hu14.18K322A mAb treatment
Trial: 32170554
Drug: Gefitinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib plus chemotherapy (pemetrexed plus carboplatin)
Trial: 32171061
Drug: MOR202 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOR202 monotherapy (0.01 mg/kg to 16 mg/kg)
Trial: 32171069
Drug: Venetoclax (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (360 mg/m) in combination with chemotherapy
Trial: 32171069
Drug: Venetoclax (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (240 mg/m) during dose escalation
Trial: 32171104
Drug: S-1 (80-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (80-120 mg/day on days 1-14) and oxaliplatin (130 mg/m2) followed by surgery
Trial: 32172489
Drug: BI 836826
RxNorm normalized name: BI 836826
DrugBank: BI-836826 (DB17322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 836826 (CD37 antibody) at doses ranging from 1 mg to 200 mg, with a maximum tolerated dose (MTD) of 100 mg; administered as an intravenous infusion once weekly for 4 weeks.
Trial: 32173192
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with iliac leg endoprosthesis without coverage of the hypogastric artery